Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04004221
NCT04004221CompletedPhase 2

A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer

BeiGene30 sites in 2 countries113 target enrollmentStarted: June 16, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
113
Locations
30
Primary Endpoint
Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Participants with histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium
  • •Disease progression during or following treatment with at least one platinum-containing regimen for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence
  • •Participants must submit archival tumor tissue for determination of program death ligand-1 (PD-L1) expression and other biomarker analyses. PD-L1 expression will be assessed centrally, and participants who are tested as PD-L1 high are eligible.
  • •Participants must have at least one measurable lesion as defined per RECIST version 1.1 assessed by the investigator
  • •Male or female, aged ≥18 years on day of signing informed consent
  • •Participants have voluntarily agreed to participate by giving written informed consent
  • •Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
  • •Life expectancy ≥12 weeks
  • •Participant must have adequate organ function as indicated by the following screening laboratory values obtained within 7 days prior to the first study treatment
  • •Absolute neutrophil count (ANC) ≥1.5×109/L
  • •Platelets ≥100×109/L
  • •Hemoglobin ≥9 g/dL or ≥5.6 mmol /L (Note: Criteria must be met without a transfusion within 14 days of obtaining the sample)
  • •Calculated creatinine clearance ≥ 30 milliliter (mL)/min (Cockcroft-Gault formula, see Appendix 5)
  • •Serum total bilirubin ≤ 1.5 X upper limit of normal (ULN) (total bilirubin must be <4 X ULN for participants with Gilbert's syndrome)
  • •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X ULN OR ≤ 5 X ULN for participants with liver metastases
  • •Female participants are eligible to enter and participate in the study if they are of:
  • •Non-childbearing potential (ie, physiologically incapable of becoming pregnant), including any female who i) Has had a hysterectomy ii) Has had a bilateral oophorectomy (ovariectomy) iii) Has had a bilateral tubal ligation iv) Is post menopausal (total cessation of menses for ≥1 year)
  • •Childbearing potential, has a negative serum pregnancy test at screening (within 7 days before the first investigational product administration), not be breast feeding, and agree to remain abstinent (refrain from heterosexual intercourse) or uses adequate contraceptive methods that result in a failure rate of <1% per year before study entry and throughout the study until 120 days after the last investigational product administration
  • •Male participants are eligible to participate in the study if they are vasectomized or agree to use contraception during the study treatment period and for at least 120 days after the last dose of study drug

Exclusion Criteria

  • •History of severe hypersensitivity reactions to other humanized monoclonal antibodies
  • •Prior active malignancy within 2 years prior to Cycle 1 Day
  • •Prior therapies targeting PD-1 or PD-L
  • •Active brain or leptomeningeal metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments.
  • •Participants with active autoimmune diseases or history of autoimmune diseases that may relapse should be excluded.
  • •Participants should be excluded if they have conditions requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.
  • •Has history of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies
  • •With severe chronic or active infections (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal or antiviral therapy within 14 days prior to first dose of study drug.
  • •With uncontrollable pleural effusion, pericardial effusion or ascites requiring pleurocentesis or abdominal tapping less than 4 weeks
  • •Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina
  • •Known history of Human Immunodeficiency Virus (HIV)
  • •Participants with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carrier with HBV deoxyribonucleic acid (DNA) ≥500 IU/mL (or 2.5 × 103 cps/mL), or active hepatitis C should be excluded. Participant with inactive hepatitis B surface antigen (HBsAg) carrier, active HBV infection with sustained anti-HBV suppression (HBV DNA <500 IU/mL or 2.5 × 103 cps/mL) and participants whose hepatitis C has been cured (hepatitis C virus [HCV] ribonucleic acid [RNA] is lower than detection limit) can be enrolled
  • •Underlying medical conditions that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events (AEs)
  • •Prior chemotherapy, radiotherapy, immunotherapy or any investigational therapies (including Chinese herbal medicine and Chinese patent medicines) used to control cancer within 2 weeks of Cycle 1 Day
  • •AEs associated with these therapies must be Grade 0-1, baseline or stabilized (except for alopecia)
  • •Prior allogeneic stem cell or solid organ transplant
  • •Administration of a live or attenuated vaccine within 4 weeks prior to study drug administration
  • •Major surgical procedure other than for diagnosis within 28 days prior to study drug administration
  • •NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Arms & Interventions

Tislelizumab

Experimental

200mg intravenously (IV) every 3 weeks(Q3W)

Intervention: Tislelizumab (Drug)

Outcomes

Primary Outcomes

Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)

Time Frame: From the date of first dose up to approximately 2 years and 2 months

ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) assessed by Independent Review Committee (IRC) using RECIST version 1.1

Secondary Outcomes

  • Progression-Free Survival (PFS) as Assessed by IRC(From the date of first dose up to approximately 2 years and 2 months)
  • Disease Control Rate (DCR) as Assessed by IRC(From the date of first dose up to approximately 2 years and 2 months)
  • Duration of Response (DOR) as Assessed by IRC(From the date of first dose up to approximately 2 years and 2 months)
  • Overall Survival (OS)(From the date of first dose up to approximately 2 years and 2 months)
  • ORR as Assessed by the Investigators(From the date of first dose up to approximately 2 years and 2 months)
  • DOR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST(From the date of first dose up to approximately 2 years and 2 months)
  • PFS as Assessed by Investigators Per RECIST Version 1.1 and irRECIST(From the date of first dose up to approximately 2 years and 2 months)
  • DCR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST(From the date of first dose up to approximately 2 years and 2 months)
  • Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(From the date of first dose until End of Study (approximately 3 years and 9 months))

Investigators

Sponsor
BeiGene
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (30)

Loading locations...

Similar Trials

Terminated
Phase 2
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBCTriple Negative Breast CancerInflammatory Breast Cancer Stage IV
NCT03184558BerGenBio ASA29
Recruiting
Phase 2
Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTLExtranodal NK/T-cell Lymphoma
NCT06406556Sun Yat-sen University90
Completed
Phase 2
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Lung Cancer MetastaticNSCLC Stage IVAdenocarcinoma of Lung
NCT03184571BerGenBio ASA99
Unknown
Phase 1
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Squamous Cell Carcinoma of Head and Neck
NCT05027204CSPC ZhongQi Pharmaceutical Technology Co., Ltd.94
Recruiting
Phase 2
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT05241093Tarapeutics Science Inc.18